RCS - IXICO plc - Commercial agreement with PETNET Solutions Inc

IXICOAnnouncement

16/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP0579Qa&default-theme=true

RNS Number : 0579Q  IXICO plc  16 December 2024

 

IXICO PLC

 

("IXICO" or the "Company")

 

Commercial agreement with PETNET Solutions Inc,

a Siemens Healthineers Company

 

 

16 December 2024 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company")
a global leader in neuroscience imaging, using its AI-driven platform to help
advance therapy research in neurological disorders, today announced a
commercial agreement with PETNET Solutions Inc, a Siemens Healthineers company
("PETNET") to supply diagnostic imaging agents to IXICO. This new offering is
an integral part of IXICO's expansion strategy to serve its growing customer
base with the latest technologies in neuroimaging.

 

The commercial agreement will see PETNET supplying targeted imaging agents to
imaging sites used on IXICO's customers' clinical trials.  Further, the
agreement adds additional capability to IXICO's growing Tracer Management
service offering which provides customers with use guidance, logistics and
seamless integration of PET tracers in neurological clinical trials.

 

PETNET provides radioactive tracers for Positron Emission Tomography ("PET
scans"), a widely used diagnostic approach that creates detailed
three-dimensional imaging, in this use case, of the inside of the brain.
 Specific imaging agents may estimate β-amyloid neuritic plaque density in
adult patients who are being evaluated for Alzheimer's Disease (AD) and other
causes of cognitive decline.  Another tracer estimates the density and
distribution of aggregated tau neurofibrillary tangles (NFTs) in adult
patients with cognitive impairment who are being evaluated for Alzheimer's
Disease.

 

Bram Goorden, Chief Executive Officer of IXICO, commented:  ''IXICO continues
to develop its end to end imaging service for clinical trials, and we are
therefore delighted to be partnering with PETNET Solutions to provide access
and supply PET tracers.  This partnership is an integral part of an expanding
offering and our commitment to positively impacting drug discovery and
development in critical neurodegenerative illnesses such as Alzheimer's
Disease.''

 

The announcement follows a number of commercial agreements announced
throughout 2024 including significant clinical trial contract wins in
Huntingdon Disease, Parkinsonian Disorder and Alzheimer's Disease, an MRI
algorithm collaboration with Imeka, and a PET tracer supply agreement with
Life Molecular Imaging.

 

Ends

Further information:

 

IXICO plc

Bram Goorden, Chief Executive
Officer
+44 (0)20 3763 7499

Grant Nash, Chief Financial Officer

 

This is an RNS Reach announcement, and the information contained is not
considered to have a significant impact on management's expectations of the
Group's performance. RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information required to
be notified under the AIM Rules for Companies, Market Abuse Regulation or
other regulation would be disseminated as an RNS regulatory announcement and
not on RNS Reach.

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABXLFFZLLZFBK